Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Enanta Pharmaceuticals (ENTA) over the last 9 years, with Q4 2025 value amounting to $3.1 million.

  • Enanta Pharmaceuticals' Interest Expenses rose 5713.56% to $3.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $8.8 million, marking a year-over-year decrease of 696.54%. This contributed to the annual value of $7.7 million for FY2025, which is 2978.98% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Interest Expenses of $3.1 million as of Q4 2025, which was up 5713.56% from $2.4 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' Interest Expenses' 5-year high stood at $3.4 million during Q4 2023, with a 5-year trough of $1.6 million in Q2 2025.
  • Its 3-year average for Interest Expenses is $2.4 million, with a median of $2.4 million in 2025.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Interest Expenses plummeted by 4298.17% in 2024 and then skyrocketed by 5713.56% in 2025.
  • Enanta Pharmaceuticals' Interest Expenses (Quarter) stood at $3.4 million in 2023, then plummeted by 42.98% to $2.0 million in 2024, then skyrocketed by 57.14% to $3.1 million in 2025.
  • Its Interest Expenses was $3.1 million in Q4 2025, compared to $2.4 million in Q3 2025 and $1.6 million in Q2 2025.